Back to top
more

Montes Archimedes Acquisition (ROIV)

(Real Time Quote from BATS)

$11.50 USD

11.50
1,815,819

-0.15 (-1.29%)

Updated Aug 7, 2025 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GRPM

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -37.50% and 88.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.11% and 167.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -25% and 28.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 54.55% and 46.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -7.14% and 5.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RFG

Zacks Equity Research

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RFG

Zacks Equity Research

Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 60% upside potential for Montes Archimedes Acquisition (ROIV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to Buy

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 45.83% and 42.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RFG

Zacks Equity Research

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GRPM

Zacks Equity Research

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GRPM

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -38.10% and 87.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GRPM

Zacks Equity Research

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GRPM

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Zacks Equity Research

Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GRPM

Zacks Equity Research

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GRPM

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 14.29% and 72.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?